Carebox
Carebox21
About
What does Carebox do?
Carebox provides a platform that helps patients, their families, and treating physicians find and access clinical trials. It aims to simplify the often complex and frustrating process of searching for suitable clinical trials, offering a more efficient way to discover advanced treatment options.
What is Carebox's revenue?
StartupHub estimates Carebox's annual revenue at $7.7M (range $4.6M to $15.7M, 66% confidence), based on comparable companies in the sector.
Where is Carebox headquartered?
Carebox is headquartered in New York, United States.
When was Carebox founded?
Carebox was founded in 2014.
What industry does Carebox operate in?
Carebox operates in Healthcare, Electronic Health Records Systems, Genomics, HealthTech, Clinical Trials, Patient Engagement.
How many employees does Carebox have?
Carebox has approximately 45 people on record.
Ship of Theseus is developing a fleet of biologics based on the homeobox (HOX) family of transcription factors to create novel pharmaceuticals.
A nonprofit biomedical research organization leveraging AI and new organizational models to accelerate scientific progress and understand complex diseases.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
AI-powered platform for personalized health and longevity.
Automated ACMG classification, phenotype matching, and clinical reporting for genetic diagnostics, transforming raw genomic data into actionable clinical insights.
Explore cutting-edge bio technology solutions with AI, launching soon.
AI-powered platform accelerating biological research and drug discovery.
Proprietary nutritional analysis systems for wellbeing, sports, and grocery retail.
An entrant is a company tagged Genomics whose domain was first registered in the window, counted from registry records in the StartupHub directory. 3 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.